MBRX [NASD]
Moleculin Biotech, Inc.
Index- P/E- EPS (ttm)-0.64 Insider Own2.15% Shs Outstand28.58M Perf Week5.65%
Market Cap36.90M Forward P/E- EPS next Y-1.17 Insider Trans0.00% Shs Float27.96M Perf Month-28.02%
Income-18.30M PEG- EPS next Q-0.25 Inst Own14.30% Short Float1.08% Perf Quarter-3.68%
Sales- P/S- EPS this Y66.50% Inst Trans-1.52% Short Ratio2.94 Perf Half Y-39.63%
Book/sh2.54 P/B0.52 EPS next Y-14.70% ROA-21.20% Target Price12.39 Perf Year-64.01%
Cash/sh2.35 P/C0.56 EPS next 5Y- ROE-23.10% 52W Range1.02 - 3.99 Perf YTD-29.57%
Dividend- P/FCF- EPS past 5Y24.40% ROI- 52W High-65.66% Beta1.88
Dividend %- Quick Ratio13.90 Sales past 5Y- Gross Margin- 52W Low34.31% ATR0.12
Employees13 Current Ratio13.90 Sales Q/Q- Oper. Margin- RSI (14)42.32 Volatility9.17% 8.62%
OptionableNo Debt/Eq0.00 EPS Q/Q-17.90% Profit Margin- Rel Volume0.25 Prev Close1.31
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume102.44K Price1.37
Recom1.70 SMA20-4.79% SMA50-14.85% SMA200-34.68% Volume7,023 Change4.58%
May-19-22 08:05AM  
May-12-22 08:35AM  
May-10-22 08:35AM  
May-05-22 08:15AM  
May-04-22 08:15AM  
Apr-21-22 08:47AM  
Apr-14-22 08:05AM  
Apr-11-22 07:05AM  
Apr-08-22 01:05PM  
Mar-25-22 07:05AM  
Mar-23-22 08:05AM  
Mar-11-22 08:05AM  
Mar-01-22 08:35AM  
Feb-14-22 02:10PM  
09:05AM  
Feb-01-22 09:11AM  
Jan-20-22 08:40AM  
Jan-18-22 08:05AM  
Jan-12-22 10:35AM  
Jan-07-22 08:30AM  
Dec-27-21 08:05AM  
Dec-01-21 08:35AM  
Nov-12-21 08:05AM  
Nov-11-21 08:05AM  
Nov-04-21 02:30PM  
Oct-20-21 05:46PM  
Oct-19-21 09:05AM  
Oct-18-21 08:25AM  
Sep-27-21 07:05AM  
Sep-17-21 08:05AM  
Sep-08-21 08:00AM  
Aug-12-21 08:18AM  
Aug-03-21 06:29AM  
Jul-13-21 08:35AM  
Jun-22-21 08:30AM  
Jun-21-21 08:35AM  
Jun-15-21 09:05AM  
May-25-21 11:23AM  
09:05AM  
May-12-21 07:35AM  
May-11-21 08:05AM  
07:30AM  
Apr-14-21 09:38AM  
07:35AM  
Apr-06-21 07:30AM  
Mar-30-21 07:30AM  
Mar-24-21 07:30AM  
Mar-09-21 07:30AM  
Feb-10-21 04:15PM  
Feb-08-21 07:30AM  
Feb-05-21 07:30AM  
Feb-04-21 03:24AM  
Feb-03-21 08:30AM  
Feb-02-21 04:22PM  
07:30AM  
Feb-01-21 07:30AM  
Jan-29-21 09:15AM  
Jan-12-21 10:40AM  
Jan-07-21 07:30AM  
Dec-29-20 07:30AM  
Dec-17-20 07:30AM  
Dec-03-20 07:30AM  
Dec-01-20 07:30AM  
Nov-19-20 07:30AM  
Nov-13-20 07:30AM  
Oct-29-20 07:30AM  
Oct-27-20 07:30AM  
Oct-21-20 07:30AM  
Oct-13-20 07:30AM  
Oct-06-20 07:30AM  
Oct-05-20 07:30AM  
Oct-01-20 07:30AM  
Sep-29-20 07:30AM  
Sep-14-20 07:30AM  
Sep-10-20 07:30AM  
Sep-09-20 01:52PM  
07:30AM  
Aug-27-20 07:30AM  
Aug-12-20 07:30AM  
Aug-11-20 09:13AM  
Jul-21-20 09:59AM  
09:36AM  
07:46AM  
07:30AM  
Jul-16-20 11:11AM  
Jul-15-20 07:30AM  
Jul-03-20 11:30AM  
Jul-02-20 07:30AM  
Jul-01-20 05:50PM  
07:30AM  
Jun-30-20 09:00AM  
Jun-29-20 08:35AM  
Jun-25-20 07:30AM  
Jun-23-20 08:49AM  
07:30AM  
Jun-17-20 11:30AM  
Jun-16-20 07:30AM  
Jun-04-20 07:30AM  
Jun-02-20 07:30AM  
Jun-01-20 11:30AM  
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.